Researcher at NovAliX Publishes New Study Findings on Small Molecule Inhibitors (Determining the Affinity and Kinetics of Small Molecule Inhibitors of Galectin-1 Using Surface Plasmon Resonance).

A recent study conducted by researchers at NovAliX in Strasbourg, France, has explored the affinity and kinetics of small molecule inhibitors of galectin-1 using surface plasmon resonance (SPR). Galectin-1 is a protein that binds to cell surface glycoproteins and has been implicated in various cancers. The study found that SPR is a viable alternative to fluorescence polarization (FP) assays for early drug discovery screening and determining affinity estimates. This research provides valuable insights into the development of small molecule galectin-1 inhibitors. [Extracted from the article]